Income Statement (Annual)

MVTG / Mantra Venture Group, Ltd. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Revenues 3 13 3 275 199 70 1,070
Operating Expenses
  Cost Of Revenue 2 10 2 0 0 - -
  Depreciation And Amortization 31 26 31 26 41 28 60
  General And Administrative Expense 48 56 48 133 137 223 106
  Salaries Wages And Officers Compensation - - - - - 336 4,845
  Operating Expenses 1,001 706 1,375 1,568 2,110 923 5,011
Operating Income Loss -1,001 -703 -1,374 -1,294 -1,911 -853 -
Nonoperating Income Expense
  Gains Losses On Extinguishment Of Debt -60 81 0 12 2 -24 -34
  Gain On Extinguishment Of Preferred Stock Liability - - - - - - -
  Gain Loss On Disposition Of Assets1 - - - - - - -2
  Accretion Expense 0 0 3 27 111 -439 561
  Gain Loss On Sale Of Derivatives - - - - - -693 -1,965
  Interest Expense 29 33 43 44 41 -227 211
  Gain Or Loss On Sale Of Stock In Subsidiary - - - - - - -
  Nonoperating Gains Losses - - - - - -384 -103
  Nonoperating Income Expense -89 34 -46 -59 -379 -1,092 -2,109
Profit Loss -1,090 -669 -1,420 -1,353 -2,290 -1,901 -6,871
Net Income Loss Attributable To Noncontrolling Interest -53 -61 -86 -62 -74 44 -58
Net Income Loss -1,037 -609 -1,334 -1,291 -2,216 -1,945 -6,813
Redeemable Preferred Stock Dividends - - - - - - -
Net Income Loss Available To Common Stockholders Basic - - - - - - -
Earnings Per Share Basic
  Earnings Per Share Basic And Diluted - - - - -0 -0 -0
Earnings Per Share Basic Other Disclosures
  Weighted Average Number Of Share Outstanding Basic And Diluted - - - - 70,848 78,327 117,085

Peers - Miscellaneous Electrical Machinery, Equipment, and Supplies (369)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...